QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
How can global pharma harness the power of Nordic RWE?
Check out the latest issue of PharmaTimes Magazine, where our CEO Kirk Geale explains how global pharmaceutical executives can harness the power of Nordic health data.
Nordic RWD are globally unique and practitioners should not miss the opportunities available in this region. This article provides an introduction to the data and spells out some exciting use cases.
Check out the feature here!
Quantify co-authors IFPA report on Western Pacific Region’s progress towards WHO goals for psoriasis
How has the Western Pacific Region progressed towards the World Health Organization’s goals for psoriasis care? Find out in the IFPA’s (International Federation for Psoriasis Associations) recently published Index Report, co-authored by Quantify Research!
In the report, five key recommendations are presented to stakeholders:
1. Pursue reductions in psoriatic disease stigma
2. Reduce the stigma associated with mental health care from the perspectives of both patients and care providers
[…]
New-cost effectiveness evidence on nirmatrelvir/ritonaivir in the progression of COVID 19
The COVID-19 pandemic created an unprecedented burden on healthcare systems worldwide. At the annual meeting of the Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID), Quantify Research own Martina Aldvén and Marcelina Kądziela in collaboration with Pfizer presented a poster on the cost-effectiveness of nirmatrelvir/ritonavir (NV/r) compared to no anti-viral treatment in Swedish adults who are at increased risk for progression to severe COVID-19.
Cost-effectiveness was assessed by […]
Quantify attends life science forum 2023 in Denmark
Last week, our very own Mary Rosenzweig had the privilege of attending Bech-Bruun’s “Life Science Forum 2023 – the EU’s Revision of the Pharmaceutical Regulations” in Denmark. This event gathered prominent figures from the industry to discuss the first overhaul of the EU Pharmaceutical Legislation in two decades.
Central to the forum’s discussions were the effective incentives for innovation. Many participants concurred that a key challenge is […]